Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at B. Riley lowered their Q2 2025 earnings estimates for shares of Nektar Therapeutics in a note issued to investors on Monday, July 7th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings per share of ($3.43) for the quarter, down from their previous forecast of ($2.55). B. Riley currently has a “Buy” rating and a $85.00 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. B. Riley also issued estimates for Nektar Therapeutics’ Q3 2025 earnings at ($2.89) EPS, Q4 2025 earnings at ($3.06) EPS, FY2025 earnings at ($11.11) EPS, FY2026 earnings at ($11.61) EPS, FY2027 earnings at ($14.17) EPS, FY2028 earnings at ($12.89) EPS and FY2029 earnings at ($11.64) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing the consensus estimate of ($2.70) by ($0.60). The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. During the same period in the prior year, the business earned ($2.70) earnings per share.

Several other research firms have also recently weighed in on NKTR. Jefferies Financial Group raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the company from $15.00 to $30.00 in a research note on Friday, April 11th. Wall Street Zen cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $90.00 target price for the company in a research note on Friday, March 14th. BTIG Research raised their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, June 24th. Finally, HC Wainwright raised their price target on Nektar Therapeutics to $120.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $88.33.

Nektar Therapeutics Trading Up 7.4%

NASDAQ:NKTR opened at $25.10 on Thursday. Nektar Therapeutics has a 1-year low of $6.48 and a 1-year high of $37.38. The firm has a fifty day simple moving average of $13.94 and a 200 day simple moving average of $12.83. The stock has a market capitalization of $311.42 million, a PE ratio of -2.62 and a beta of 0.94.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NKTR. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Nektar Therapeutics by 12.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 730,875 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 80,034 shares during the period. Monaco Asset Management SAM increased its position in Nektar Therapeutics by 1.8% during the 4th quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company’s stock valued at $1,891,000 after purchasing an additional 35,648 shares during the period. Sei Investments Co. increased its position in Nektar Therapeutics by 50.6% during the 4th quarter. Sei Investments Co. now owns 94,152 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 31,654 shares during the period. JPMorgan Chase & Co. increased its position in Nektar Therapeutics by 29.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,182,995 shares of the biopharmaceutical company’s stock valued at $1,100,000 after purchasing an additional 269,695 shares during the period. Finally, Wellington Management Group LLP increased its position in Nektar Therapeutics by 10.4% during the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 49,319 shares during the period. Institutional investors and hedge funds own 75.88% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.